Injection Adipocytolysis for Body and Jawline Contouring: Real-World Experience and Treatment Considerations

Abstract

Background: The role of ATX-101 in submental fat reduction has been well documented; however, its applicability across multiple anatomic areas is to be explored.

Objectives: The authors sought to describe the experience with ATX-101 subcutaneous injections for body and jawline contouring and evaluate its safety.

Methods: This single-arm, single-center observational study included 201 patients who underwent injection adipocytolysis with ATX-101 (area-adjusted dose of 2 mg/cm2) in the jowl, abdomen (upper/lower), thigh (inner/outer/banana roll), arm, anterior periaxillary fat, back (lower/upper/nape/lipoma), knee (anterior/medial), chest, and/or neck. The number of treatment sessions, treatment volumes, doses, injections required for each anatomic area, and associated adverse events were recorded.

Results: The mean number of treatment sessions conducted was 1.8. Multiple sessions were common for the jowl (mean: 2.0 and mean volume administered varied significantly between persons receiving 1 or multiple sessions [P = 0.005]). The mean volume and mean number of injections per session were highest in the chest (84.7 mL and 423.5, respectively) and lowest in the jowl (0.8 mL and 4.6, respectively). The chest (0.2 mL) and nape (0.2 mL) received the highest mean ATX-101 dose per injection site per session, whereas the inner thigh (0.11 mL) and upper back (0.11 mL) received the least. Adverse events observed were localized to the injection site. All patients experienced edema after each session, whereas numbness, tenderness, bruising, and paresis were experienced by 99.6%, 94.2%, 33.1%, and 2.6% of patients, respectively. Alopecia was not observed.

Conclusions: ATX-101 was well tolerated for body and jawline contouring.

Figure 1.

Images of this 47-year-old female patient who received 1 treatment with 36 mL of ATX-101 in the lower abdomen. (A, C) Front and lateral views of the abdomen prior to ATX-101 injections and (B, D) front and lateral views of the abdomen 3 months after treatment.

Figure 2.

Images of this 52-year-old male patient who received 1 treatment with ATX-101 in the lower and upper abdomen (47 cc to the right and 47 cc to the left). (A) Abdomen prior to ATX-101 injections, (B) abdomen 3 months after treatment, and (C) abdomen 5 months after treatment.

Figure 3.

Images of this 44-year-old female patient who received 3 treatments with ATX-101 in the jowl. (A, C, E) Front, oblique, and lateral views of the jowl prior to ATX-101 injections, and (B, D, F) front, oblique, and lateral views of the jowl 3 months after her third treatment.

Figure 4.

Images of this 38-year-old female who received ATX-101 to her right and left anterior periaxillary fat. (A) Anterior periaxillary fat before her first treatment and (B) anterior periaxillary fat 1 day after her first treatment showing signs of edema, erythema, and bruising.